Drug Trial Radar · NCT05002998
TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
313
Actual
Start
Sep 16, 2021
Primary completion
Dec 19, 2025
Study completion Dec 19, 2025
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of Thyroid Eye Disease (TED) in adult participants. This international, Phase 3b/4 trial is being conducted to fulfill an FDA post-marketing requirement for a descriptive trial to evaluate the safety, efficacy and need for re-treatment of 3 different teprotumumab treatment durations for TED. In addition, serum samples from participants with a Baseline Clinical Activity Score (CAS) ≥3 will be evaluated for biomarkers of disease.
Conditions
- Thyroid Eye Disease
Interventions
TeprotumumabDrug
Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20-mL glass vials as a freeze-dried powder containing, in addition to the drug substance, 20 mmol/L histidine-histidine chloride, 250 mmol/L trehalose and 0.01% polysorbate 20 (w/w). Prior to administration, each vial containing 500 mg teprotumumab freeze-dried powder will be reconstituted with 10 mL of sterile water for injection. The resulting solution will have a concentration of 47.6 mg/mL teprotumumab-trbw antibody. The reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration
PlaceboDrug
Placebo will consist of a normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as appropriate, per weight-based dosing volumes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants who experience at least 1 treatment-emergent adverse event (TEAE) and the percentage of participants who experience at least 1 treatment emergent AESI during treatment with teprotumumabTime frame: Screening to End of Study (last visit possible is Week 136)
- Percentage of Participants who receive re-treatmentTime frame: Week 27 to Week 136
Locations
28 sites in 6 countries. Site status is shown where the registry gives one.
The Private Practice of Raymond Douglas, MD - Beverly Hills
Beverly Hills, California
USC Roski Eye Institute - Los Angeles
Los Angeles, California
Stanford University
Palo Alto, California
University of Colorado - Eye Center - PPDS
Aurora, Colorado
Bascom Palmer Eye Institute
Miami, Florida
Mayo Clinic - PPDS
Rochester, Minnesota
Casey Eye Institute - OHSU
Portland, Oregon
Hôpital Claude Huriez-Lille-Rue Michel Polonovski
Lille, France
Centre Hospitalier National D'ophtalmologie Des Quinze Vingts
Paris, France
Hopital Jean Minjoz
Besançon, Doubs, France
Hospices Civils de Lyon - Hôpital Louis Pradel
Bron, Rhône, France
Universitätsklinikum Essen
Essen, Germany
Universitätsklinikum Münster
Münster, Germany
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, Germany
University Medicine Göttingen Germany
Göttingen, Lower Saxony, Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Rhineland-Palatinate, Germany
Azienda Ospedaliera Universitaria Federico II
Naples, Campania, Italy
ASST dei Sette Laghi - Ospedale Di Circolo E Fondazione Macchi
Varese, Lombardy, Italy
ARNAS Garibaldi - PO Garibaldi-Centro
Catania, Sicily, Italy
Azienda Ospedaliero Universitaria Pisana - Stabilimento Santa Chiara
Pisa, Tuscany, Italy
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Hospital La Arruzafa
Córdoba, Córdoba, Spain
Southampton University Hospitals NHS Trust
Southampton, United Kingdom
Moorfields Eye Hospital - PPDS
London, London, City of, United Kingdom
Imperial College Healthcare NHS Trust - PPDS
London, London, City of, United Kingdom
University Hospital of Cardiff
Cardiff, South Glamorgan, United Kingdom
Royal Victoria Infirmary
Newcastle upon Tyne, Tyne and Wear, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.